For female participants with myasthenia gravis, pregnancy is not associated with an increased risk of serious flare-ups of ...

For females with myasthenia gravis, pregnancy is not associated with an increased risk of serious flare-ups of the disease, ...

The label expansion will include adults with AChR-Ab-negative gMG, making efgartigimod the first and only approved treatment for all serotypes of the rare neuromuscular disease.

Label expansion enables serotype-agnostic use of FcRn blockade in adult gMG, positioning both IV Vyvgart and SC Vyvgart Hytrulo as first approved options regardless of antibody status. ADAPT SERON ...

Myasthenia gravis is a rare chronic condition that affects an estimated 150 to 200 out of every million people globally.

What is MG: An autoimmune neuromuscular disorder where antibodies disrupt nerve-to-muscle communication, causing fluctuating weakness in muscles used for vision, speech, swallowing, movement, and ...

VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and ...

Argenx (ENXTBR:ARGX) shareholders recently approved Karen Massey as CEO following Tim Van Hauwermeiren's retirement. The company is reiterating its Vision 2030 plan under the new leadership, signaling ...

The first quarter 2026 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 PM CET/8:30 AM ET. A webcast of the live call may be ...

Tapia, MD, PhD, discusses the results of the ADAPT OCULUS trial, which found promising results for treating patients with ...

The timing of myocarditis onset during immunotherapy treatment for cancer may predict how likely a person is to die of the condition, according to retrospective study results.Patients who developed my ...